Novel approaches to the treatment of Pseudomonas aeruginosa infections in cystic fibrosis

Matthew N. Hurley*, Miguel Cámara, Alan R. Smyth

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

95 Citations (Scopus)


Pseudomonas aeruginosa chronically infects patients with cystic fibrosis and is associated with greater morbidity. There has been limited progress on the clinical development of new antibiotics with novel modes of action. This review addresses some of the latest research developments on the exploitation of candidate adjuvant therapeutic agents that may act alongside conventional antibiotics as an alternative therapeutic strategy. After considering key mechanisms this opportunistic pathogen employs to control virulence, the progress of various strategies including the inhibition of quorum sensing, efflux pumps and lectins, and the use of iron chelators, bacteriophages, immunisation and immunotherapy is reviewed. Both therapeutic approaches in early development and clinical phase are discussed. Copyright

Original languageEnglish
Pages (from-to)1014-1023
Number of pages10
JournalEuropean Respiratory Journal
Issue number4
Publication statusPublished - 01 Oct 2012
Externally publishedYes


  • Antibiotic resistance
  • Antibiotic treatment
  • Cystic fibrosis and chronic infections
  • Pseudomonas

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine


Dive into the research topics of 'Novel approaches to the treatment of Pseudomonas aeruginosa infections in cystic fibrosis'. Together they form a unique fingerprint.

Cite this